News

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Merck stock has more than doubled over the past five years, and the latest Discounted Cash Flow (DCF) intrinsic value estimate now points to a sizeable gap versus the current share price, while the broader valuation checks suggest a more mixed picture. The roughly 102% total return over five years highlights how strongly the market has rewarded Merck over a full cycle and raises the bar for any further upside to be justified by fundamentals. Recent news around the FDA approval of the oral...

In the most recent trading session, Merck (MRK) closed at $130.36, indicating a -1.11% shift from the previous trading day.

The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.

MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.

GILD heads into Q2 earnings with HIV franchise strength, rising Yeztugo expectations and oncology progress, even as Cell Therapy faces competitive pressure.

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.

One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.

AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms it.

Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (NYSE:MRK) reported that KEYTRUDA met its primary endpoint of progression free survival in the Phase 3 KEYNOTE C93 trial for advanced or recurrent endometrial cancer. The company highlighted this as the first time a PD 1 inhibitor has shown a statistically significant benefit over platinum chemotherapy in this patient population. The data are described as a high impact development for Merck's oncology portfolio, with potential implications for future regulatory filings. For investors...

In July 2026, Aurobindo Pharma announced a royalty-free, non-exclusive licensing deal with Merck to supply generic alimatravir for HIV prevention across 129 low- and middle-income countries, while Merck also secured U.S. FDA approval for LIPFENDRA, the first oral PCSK9 inhibitor for lowering LDL cholesterol. Together, these moves highlight Merck’s twin push to expand access to an investigational monthly HIV PrEP pill globally and grow its cardiovascular portfolio with a new oral...

Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strokes. Scribe’s therapies turn off the genetic instructions leading to high levels of damaging lipids, without having to cut a gene’s DNA strands like other one-shot genetic treatments in the clinic.

The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.

BMY heads into Q2 earnings with growth drugs driving momentum as legacy products decline, setting the stage for a closely watched earnings report.

Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.

LGND stock has risen more than 56.5% so far in 2026. Ligand doesn't make drugs; it forks over funding in exchange for Big Pharma royalties.

AstraZeneca tops Q2 earnings and revenue estimates as strong demand for oncology and rare disease drugs helps offset growing generic competition across key products.

Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep investors focused on upcoming pipeline catalysts.

IMCR's Kimmtrak sales climbed 29% in 2025 on wider adoption, with pivotal 2026 trial results set to test its next expansion opportunity.

The company that used to reassure you with its sheer breadth now leads with a push to dominate oncology, and a holder who bought a diversified compounder should notice the bet has changed shape.

Applying the Dogs of the Dow logic across the entire S&P 500 sounds like a recipe for chasing troubled dividends, but a holding-by-holding look at SDOG reveals a more complicated picture, with two positions that deserve serious scrutiny before you commit capital.

Management's plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.

Eli Lilly just won FDA clearance for an oral GLP-1 that targets over one billion potential patients worldwide, and the stock has barely moved. Here is whether that disconnect signals a buying opportunity or a trap.

Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, undergoes FDA review & gains new development collaborations.

GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.

If you're looking for more frequent payouts, you can still enjoy the benefits of low fees and broad diversification, thanks to these top monthly dividend ETFs.

Merck (MRK) is back in focus for investors after the US Food and Drug Administration approved LIPFENDRA, the first oral PCSK9 inhibitor. This adds a new cardiovascular drug to the company’s portfolio. See our latest analysis for Merck. Merck’s share price is $127.47, with a 30-day share price return of 10.38% and a year-to-date share price return of 19.75%. The 1-year total shareholder return of 56.86% reflects strong momentum alongside frequent product and trial updates. If LIPFENDRA’s...